Patients Achieving Good Glycemic Control (HBA1c <7%) Experience a Lower Rate of Hypoglycemia With Insuin Degludec Than With Insuline Glargine: A Meta-Analysis of Phase 3A Trials
Omitting Late Night Eating May Cause Hypoglycemia In "Well Controlled" GBasal Insulin-treated Type 2 Diabetes
Liraglutide Achieves A1C Targets More Often Than SitaGliptin or Exenatide When Added To Metformin in Patients With Type 2 Diabetes and a Baseline A1C <8%
How much do I give? Dose estimation formulas for once-nightly insulin Glargine and pre-meal insulin Lispro in type 1 diabetes mellitus
Contribution of the Dawn Phenomenon To the Fasting and Postbreakfast Hyperglycemia in Type 1 Diabetes Treated With Once-nightly Insulin Glargine
Misled by the Morning “Fasting” Plasma Glucose
No Higher Dose Requirements with Insulin Detemir than Glargine in Type 2 Diabetes: A Crossover, Double-Blind, and Randomized Study Using Continuous Glucose Monitoring
Continuous Glucose Monitoring-Guided Insulin Dosing in Pump-Treated Patients with Type 1 Diabetes: A Clinical Guide
A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing
A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing
The Variable Weight Effect of Exenatide Treatment
Titrating Beyond Glycemic Goal: “Post-Glycemic Target Phenomenon”
Accuracy of Dosage Volume for Halfway Doses in the Victoza Pen
Weight versus Pre-Insulin-Treatment Assessment of Insulin Sensitivity to Determine the Starting Basal Insulin Dose: A Faster Way to Get to Goal?